Aurobindo Pharma arm, Luoxin to form JV in China

To make nebuliser inhaler, other products for U.S., EU

December 11, 2018 09:41 pm | Updated 10:30 pm IST - HYDERABAD

Aurobindo Pharma’s arm Helix Healthcare BV will form a joint venture in China to manufacture nebuliser inhaler and other products for China, U.S. and EU markets.

Helix, the company’s wholly-owned subsidiary in The Netherlands, has entered into an agreement with Chinese firm Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. to form a joint venture in China, the drug maker said on Tuesday.

Manufacturing units

The JV would have manufacturing facilities to make nebuliser inhaler products for the China, U.S. and EU markets.

It will undertake contract manufacturing for non-nebuliser inhaler products.

Commencement of commercial production by the joint venture firm is expected during 2021, the company said in a regulatory filing. The estimated total project cost, including working capital for the JV company, would be $50 million.

“The percentage of shareholding in the JV company will be 30% and 70% between Helix and Luoxin [respectively],” Aurobindo Pharma said.

Helix will invest $15 million and Luoxin $35 million in the form of equity in a phased manner. Luoxin has the right to appoint three directors, while Helix can appoint one director in the proposed JV.

For Europe markets, the proposed JV ‘would establish fully-owned subsidiaries in any of the European countries’.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.